MDS

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 6, 2023
Research, American Society of Hematology, Therapy, Obesity, MDS, Myelodysplastic syndrome, 65th National Film Awards, Syndrome, Orthostatic hypertension, KROS, Ruxolitinib, Protein, Society, Disorder, Abstract, Hand, Part, Exposition, Investment, Patient, Pharmaceutical industry

Keros expects to initiate the KER-065 Phase 1 clinical trial in a healthy adult population in the first quarter of 2024.

Key Points: 
  • Keros expects to initiate the KER-065 Phase 1 clinical trial in a healthy adult population in the first quarter of 2024.
  • Keros reported a net loss of $39.4 million in the third quarter of 2023 as compared to a net loss of $23.5 million in the third quarter of 2022.
  • Keros’ cash and cash equivalents as of September 30, 2023 was $287.9 million compared to $279.0 million as of December 31, 2022.
  • Keros expects that the cash and cash equivalents it had on hand at September 30, 2023 will enable Keros to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025.

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

Retrieved on: 
Thursday, November 2, 2023
Research, NSCLC, EP300, IND, Thrombocytopenia, MDS, Preclinical development, Colorectal cancer, Merck, Chromatin, Factorization of polynomials, Prostate cancer, Hanson, LDAC, ARID1B, Clinical trial, CBP, BRG1, BRM, Safety, Investment, AR, Patient, Gene expression, BAF, Prostate, Mutation, State Administrative Expenses, Cancer, Pharmaceutical industry, Vaccine, Decitabine, Foghorn, AML

“During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024.

Key Points: 
  • “During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024.
  • Foghorn commenced a Phase 1 study of FHD-286 in combination with decitabine or low-dose cytarabine (LDAC) in relapsed and/or refractory AML patients, with the first patient dosed during the third quarter of 2023.
  • As of September 30, 2023, the Company had $259.9 million in cash, cash equivalents and marketable securities, which provides cash runway into the first half of 2026.
  • Net loss was $14.3 million for the three months ended September 30, 2023, compared to a net loss of $25.8 million for the three months ended September 30, 2022.

Vincerx Pharma To Present Three Posters at ASH 2023 in December

Retrieved on: 
Thursday, November 2, 2023
Acute lymphoblastic leukemia, Therapy, University of Calgary, MDS, Drug resistance, Myelodysplastic syndrome, CD123, Activity, Novel, Safety, PALO, Humanized antibody, CDK9, PM, CXCR5, Drug, Society, ASH, Hematology, ADC, Lymphoid neoplasms with plasmablastic differentiation, MCL, University, Pharmacology, Cancer, Lymphoid leukemia, Cellular, Patient, Transplant, Model, Fine chemical, Medicinal plants, Flour

PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it will present three posters related to VIP943 (NCT06034275), VIP924 (in preclinical studies), and enitociclib (in collaboration with University of Calgary) at the 65th American Society for Hematology Meeting (ASH), taking place in San Diego California from December 9 to 12, 2023.

Key Points: 
  • "The three ASH 2023 posters highlight the strong scientific foundation for Vincerx’s programs.
  • “In addition, we are pleased to share preclinical data related to the activity of VIP924, a first-in-class CXCR5 ADC for the treatment of B-cell malignancies.
  • Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
    Presentation Time: 6:00 PM - 8:00 PM, Pacific Standard Time
    Title: Targeting CDK9 in KMT2A-Rearranged Infant Leukemia: Evidence for Activity and Drug Synergy with Enitociclib
    Session Name: 616.
  • Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
    Presentation Time: 6:00 PM - 8:00 PM, Pacific Standard Time

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

Retrieved on: 
Thursday, November 2, 2023
CSU, Acute myeloid leukemia, Jasper, Japan America Society of Greater Philadelphia, Cure, MDS, CD117, Syndrome, Myelodysplastic syndrome, ASH, Risk, Radiation, HCT, Exposition, Therapy, Toxicity, Monoclonal antibody, AML, Toxic epidermal necrolysis, Vaccine

The study being presented demonstrated that a regimen of briquilimab plus Flu/TBI leads to successful engraftment of donor blood stem cell without the associated short and long-term toxicities that accompany busulfan-based regimens commonly used in transplant of donor or gene-corrected cells.

Key Points: 
  • The study being presented demonstrated that a regimen of briquilimab plus Flu/TBI leads to successful engraftment of donor blood stem cell without the associated short and long-term toxicities that accompany busulfan-based regimens commonly used in transplant of donor or gene-corrected cells.
  • Based on its mechanism of action, briquilimab is known to potently synergize with radiation, leading to stem cell depletion without increasing off-target toxicity.
  • “We are pleased to be able to present positive final results from this study in an oral presentation at the ASH Annual Meeting, which support a favorable safety profile for briquilimab as well as its clinical potential in a variety of indications and patient types,” said Edwin Tucker, M.D., Chief Medical Officer of Jasper.
  • “While we have more recently prioritized our development efforts in addressing mast cell diseases, we continue to enroll a Phase 1 trial evaluating briquilimab as a second-line therapy in subjects with LR-MDS and look forward to presenting data from that study next year.”
    Details of the presentation are as follows:
    Abstract Title: Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission and Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation

Agios Reports Business Highlights and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Anti-transglutaminase antibodies, Research, RISE, PKU, Research and development, IND, AGIO, Rare, Sickle cell disease, MDS, Public expenditure, Enrollment, SG, Pyruvate kinase deficiency, R, Society, Phenylketonuria, ASH, Thalassemia, PK, Security, Abstract, Phenylalanine hydroxylase, TMPRSS6, Agios Pharmaceuticals, PAH, Agios, Patient, Administration, Nursing, Cryptocurrency, Pharmaceutical industry, Medical device, Video game, Alnylam Pharmaceuticals

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported business highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Launch: Generated $7.4 million in U.S. net revenue for the third quarter of 2023, a 10 percent increase over the second quarter of 2023.
  • A total of 160 unique patients have completed prescription enrollment forms, representing an increase of 9 percent over the second quarter of 2023.
  • Net Loss: Net loss was $91.3 million for the third quarter of 2023 compared to $81.7 million for the third quarter of 2022.
  • ET to discuss third quarter 2023 financial results and recent business activities.

Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Standard of care, Acute myeloid leukemia, AIM, MDS, Nasdaq First North, MD, Safety, Doctor of Philosophy, Poster, Syndrome, Society, ASH, Majesty of the Seas, Efficacy, Cancer, Faron Pharmaceuticals, University, SOC, Exposition, Cellular, MD Anderson Cancer Center, Patient, Transplant, Associate, AML, Pharmaceutical industry, Leukemia

The ASH Annual Meeting will take place from 9-12 December, 2023, in San Diego, California and virtually.

Key Points: 
  • The ASH Annual Meeting will take place from 9-12 December, 2023, in San Diego, California and virtually.
  • The poster will contain updated clinical data from the study.
  • Encouraging Efficacy Observed in BEXMAB Study: A Phase 1/2 Study to Assess Safety and Efficacy of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies
    Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
    Dr. Mika Kontro, MD, PhD, Associate Professor at the University of Helsinki; Dr.
  • Naval Daver, MD, Associate Professor of Leukemia at The University of Texas MD Anderson Cancer Center
    The full abstract, which contains data up to July 25, 2023, when the abstract was submitted, is available online on the ASH Annual Meeting & Exposition website: 65th ASH Annual Meeting & Exposition - Hematology.org

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Wednesday, November 1, 2023
Research, AD, Food, Health care, Biomarker, ATCC, Macrophage, World Intellectual Property Organization, Data, White matter, Phase, MHRA, MRI, MDS, CELL, Hereditary leiomyomatosis and renal cell cancer syndrome, Prostate cancer, Dementia, China International Search and Rescue Team, ATCC (company), Phagocytosis, EEG, Cancer, Patient, MS, BOCA, Human, Neurodegenerative disease, Conference, CTA, Patent Cooperation Treaty, AAIC, PCT, NK, Brain, Remyelination, Grey, AML, Carcinoma, FDA, IND, Medication, CNS, Treatment-resistant depression, Drug development, Pharmacotherapy, Neuroinflammation, WIPO, Cross, Cognition, Vaccine, Pharmaceutical industry, Medical imaging, Cryptocurrency, Health, Immunotherapy, Disease

BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.
  • Recruitment of the trial is increasing and the company anticipates results of the Phase II program towards the end of 2024.
  • Other expense was approximately $0.0 million for the quarter ended September 30, 2023, compared to approximately $0.3 million during the quarter ended September 30, 2022.
  • Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.

Lavras Gold appoints Naomi Nemeth to the position of Vice President, Investor Relations

Retrieved on: 
Wednesday, November 1, 2023
Journalism, Gold, Mining, MDS, LGC, Copper, Geology, Brock University, Communication, OTCQB, Clarica, Democratic republic, Biology, University, Congo, Manulife, GSK plc

TORONTO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lavras Gold Corp. (TSXV: LGC, OTCQB: LGCFF) is pleased to announce the appointment of Naomi Nemeth to the newly created position of Vice President, Investor Relations.

Key Points: 
  • TORONTO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lavras Gold Corp. (TSXV: LGC, OTCQB: LGCFF) is pleased to announce the appointment of Naomi Nemeth to the newly created position of Vice President, Investor Relations.
  • Ms. Nemeth will be responsible for building and maintaining a comprehensive investor relations program, for communicating with both institutional and retail investors globally and for furthering the development of Lavras Gold’s business and growth strategy.
  • Naomi Nemeth is a seasoned Investor Relations professional with more than 25 years' experience.
  • In addition, Ms. Nemeth has held senior Investor Relations and Communications roles within the pharmaceutical industry (Biovail, MDS, Glaxo) and the financial services sector (Clarica, Manulife).

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Retrieved on: 
Monday, October 30, 2023
ASX, MSA, Research, DTI, MRI, Tax, Neuroimaging, Biomusic, International Congress on Tuberculosis, DMC, Patent, Biomarker, MDS, Pathology, R, Data monitoring committee, Drug development, Pharmacokinetics, Multiple system atrophy, Australian Taxation Office, Research and Development Tax Incentive, Disease, ATH, European Patent Office, SAN, Movement disorder, Brain, Safety, European Patent Convention, Patient, Treating, Diagnosis, Vanderbilt University Medical Center, Iron, Pharmaceutical industry, Alterity

MELBOURNE, Australia and SAN FRANCISCO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2023 (Q1 FY24).

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2023 (Q1 FY24).
  • In addition, an independent Data Monitoring Committee (DMC) recommended that the trial continue as planned and they expressed no concerns about safety.
  • Today, Alterity announced that screening has closed for its ATH434-201 Phase 2 clinical trial, an important step to completing enrollment in the study.
  • 3938364 covers more than 150 novel pharmaceutical compositions that are designed to redistribute the excess iron implicated in neurodegenerative diseases.

Netsmart Showcases Advancements Driving Value-Based Care Success for Senior Living Providers at LeadingAge 2023

Retrieved on: 
Monday, November 6, 2023
Nursing, Data Management, Practice Management, Technology, Managed Care, Other Health, Health, General Health, Seniors, Software, Consumer, Intelligence, Ageing, Medicine, SVP, General number field sieve, MDS, EHR, ONC, Communication

At booth 1206, LeadingAge attendees can discover next-generation technology innovations and offerings of the CareFabric platform that are driving digital transformation for post-acute care organizations.

Key Points: 
  • At booth 1206, LeadingAge attendees can discover next-generation technology innovations and offerings of the CareFabric platform that are driving digital transformation for post-acute care organizations.
  • Netsmart is empowering senior living providers with a platform that serves the post-acute care continuum, including home health and hospice, designed to optimize operations, target clinical quality and outcomes, and maximize your reimbursement.
  • We're dedicated to empowering providers through innovative solutions, staff burdens, enhancing efficiency, and ultimately supporting care for the aging services field."
  • Senior living providers attending the LeadingAge Annual Meeting & Expo can schedule a meeting and stop by booth 1206 to connect with industry leaders, experience innovative technology and discover how Netsmart is helping organizations transform value-based care models.